LOS ANGELES– The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Instadose Pharma Corp. (“Instadose” or “the Company”) (OTC: INSD) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The SEC announced a temporary suspension in the trading of Instadose securities on November 23, 2021. The SEC based this action on concerns about both the accuracy and adequacy of information about the Company available to the market. The regulators noted the Company’s shares have jumped in price and trading volume in a manner not supported by its assets and financials. There are also concerns about trading associated with individuals related to a person with control of the Company and the operations of the Company’s Canadian subsidiary. Based on these facts, shares of Instadose dropped by 13% on the same day.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
